The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed Jun 17, 2019. Its latest SEC filing is a 15-12G from Jun 21, 2019.
10-Q for Q3 FY2019, filed Jun 17, 2019
The sections below describe the company as of the FY2018 annual report.
Develops small-molecule drug candidates and engineered proteins for Parkinson’s and Alzheimer’s diseases, and seeks biotechnology and pharmaceutical companies as development and commercialization partners.
10-K for FY2018, filed Jul 16, 2018We are a preclinical stage biotechnology company focusing on commercializing novel therapies and the intellectual property generated from…View ↗
Focusing on specific therapeutic targets we thoroughly investigate target family biophysics, bringing together a combination of drug…View ↗
In addition, we are pursuing the application of protein delivery technologies that enable the delivery of proteins into patients’ brain…View ↗
Strategically collaborate or in- and out-license select programs.View ↗
No revenue was reported.
10-K for FY2018, filed Jul 16, 2018
Plans to collaborate with biotechnology or pharmaceutical companies and license selected candidates to them for development and commercialization.
10-Q for Q3 FY2019, filed Jun 17, 2019
$343KView ↗
8-K, filed Mar 21, 2019
On March 13, 2019, Simon Peace’s employment agreement as the Chief Financial Officer of Cantabio Pharmaceuticals Inc. (the “Company”)…View ↗
Loading...
